September 16, 2011
Pool N58, RNA, DAT
Figure 1. Using a specific nucleic aptamer to inhibit the dopamine transporter would initially create a buildup of dopamine in the synaptic cleft and increase receptor activity. Over time the amount of dopamine released would decrease, detrimental neurotoxins would be unable to enter presynaptic cells through DAT, and the symptoms of dopamine related disorders may be alleviated. Picture adapted from the “Dopamine Receptors” website.
Here is a link to my project proposal.
Here is a link to Progress Report 1.